Search Results - "Rüter, Björn Hans"

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group by LÜBBERT, Michael, SUCIU, Stefan, BEELDENS, Filip, MUUS, Petra, PFLÜGER, Karl-Heinz, COENS, Corneel, HAGEMEIJER, Anne, ECKART SCHAEFER, Hans, GANSER, Arnold, AUL, Carlo, DE WITTE, Theo, WIJERMANS, Pierre W, BAILA, Liliana, RÜTER, Björn Hans, PLATZBECKER, Uwe, GIAGOUNIDIS, Aristoteles, SELLESLAG, Dominik, LABAR, Boris, GERMING, Ulrich, SALIH, Helmut R

“…To compare low-dose decitabine to best supportive care (BSC) in higher-risk patients with myelodysplastic syndrome (MDS) age 60 years or older and ineligible…”
Get full text

Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG) by Becker, Heiko, Suciu, Stefan, Rüter, Björn Hans, Platzbecker, Uwe, Giagounidis, Aristoteles, Selleslag, Dominik, Labar, Boris, Germing, Ulrich, Salih, Helmut R., Muus, Petra, Pflüger, Karl-Heinz, Hagemeijer, Anne, Schaefer, Hans-Eckart, Fiaccadori, Valeria, Baron, Frédéric, Ganser, Arnold, Aul, Carlo, de Witte, Theo, Wijermans, Pierre W., Lübbert, Michael

“…In the European Organisation for Research and Treatment of Cancer (EORTC)/GMDSSG phase III trial 06011, we compared decitabine (15 mg/m 2 every 8 h for 3 days)…”
Get full text